2 results
Approved WMOPending
The primary efficacy objective for this study is to demonstrate non-inferiority of ocrelizumab compared with fingolimod
Approved WMORecruiting
The objective of the study is to assess the long-term safety and efficacy of intravenous ATB200 co-administration with oral AT2221 in adult subjects with late-onset Pompe disease.